Cargando…
Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers
BACKGROUND: Tenapanor, a small molecule with minimal systemic availability, is a first-in-class sodium/hydrogen exchanger 3 (NHE3) inhibitor that acts in the gut. Here, we evaluate the pharmacodynamics and safety of tenapanor in healthy adults. METHODS: Two phase I, single-center, randomized, double...
Autores principales: | Rosenbaum, David P., Yan, Andrew, Jacobs, Jeffrey W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856883/ https://www.ncbi.nlm.nih.gov/pubmed/29363027 http://dx.doi.org/10.1007/s40261-017-0614-0 |
Ejemplares similares
-
A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
por: Johansson, Susanne, et al.
Publicado: (2016) -
The NHE3 Inhibitor Tenapanor Prevents Intestinal Obstructions in CFTR-Deleted Mice
por: Tan, Xinjie, et al.
Publicado: (2022) -
Tenapanor administration and the activity of the H(+)‐coupled transporter PepT1 in healthy volunteers
por: Johansson, Susanne, et al.
Publicado: (2017) -
Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study
por: Johansson, Susanne A., et al.
Publicado: (2017) -
Preclinical and Healthy Volunteer Studies of Potential Drug–Drug Interactions Between Tenapanor and Phosphate Binders
por: Johansson, Susanne, et al.
Publicado: (2016)